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INTRODUCTION
In many healthcare systems, chest X-ray 
(CXR) remains the first-line test for lung 
cancer for patients who are symptomatic. 
The relatively poor survival rates of people 
with lung cancer in countries such as the UK, 
compared with other countries, may be partly 
due to the disease being diagnosed in its later 
stages.1,2 More evidence on the accuracy of 
CXR to determine whether it has sufficient 
sensitivity and specificity for lung cancer, and 
whether certain symptoms confer a greater 
risk that warrants immediate referral for 
alternative investigations, even following a 
negative CXR, is required. 
In the UK, guidance from the National 
Institute for Health and Care Excellence 
(NICE) on lung cancer diagnosis3 draws 
on the positive predictive values (PPVs) of 
symptoms, which have been derived from 
cohort and case-control studies.4–6 NICE 
guidance recommends CXR for several 
symptoms in patients aged >40 years.3 In 
turn, findings on CXR that are suspicious 
of lung cancer warrant an urgent referral, 
which means the individual should be seen 
by a specialist within 2 weeks; this is known 
as a 2-week wait or TWW referral. As a 
result of its relatively high PPV — reported at 
2.4% by William Hamilton4 — the presence 
of unexplained haemoptysis is considered 
justification to initiate a TWW referral 
irrespective of CXR results. 
Although guidance for GPs is clear on 
when to consider a CXR and the action to take 
if an X-ray is abnormal, what GPs should do 
when CXR does not indicate grounds for TWW 
referral is less clear. A recent systematic 
review7 estimated that CXR detects lung 
cancer in approximately 77%–80% of cases 
in the year before diagnosis; in addition, 
audits8,9 have suggested that negative CXR 
results in patients later diagnosed with lung 
cancer may contribute to a delay in diagnosis. 
The study presented here utilised routinely 
collected data for patients aged >50 years 
who presented to a service that allowed them 
to request a CXR (a self-requested CXR, 
or SR-CXR) if they had any symptom that, 
according to NICE,3 warrants CXR. 
The study aimed to:
• determine the sensitivity and specificity 
of CXR for lung cancer in patients with 
symptoms aged >50 years, who requested 
the investigation;
• estimate the risk (PPVs) of being diagnosed 
with lung cancer within 1 year and 2 years 
following a negative CXR result for a range 
of symptoms and symptom combinations; 
and
• determine whether the symptoms 
Abstract
Background
Chest X-ray (CXR) is the first-line investigation 
for lung cancer in many countries but previous 
research has suggested that the disease is not 
detected by CXR in approximately 20% of patients. 
The risk of lung cancer, with particular symptoms, 
following a negative CXR is not known.
Aim
To establish the sensitivity and specificity of CXR 
requested by patients who are symptomatic; 
determine the positive predictive values (PPVs) 
of each presenting symptom of lung cancer 
following a negative CXR; and determine whether 
symptoms associated with lung cancer are 
different in those who had a positive CXR result 
compared with those who had a negative CXR 
result.
Design and setting
A prospective cohort study was conducted in 
Leeds, UK, based on routinely collected data from 
a service that allowed patients with symptoms of 
lung cancer to request CXR.
Method
Symptom data were combined with a diagnostic 
category (positive or negative) for each CXR, and 
the sensitivity and specificity of CXR for lung 
cancer were calculated. The PPV of lung cancer 
associated with each symptom or combination of 
symptoms was estimated for those patients with 
a negative CXR.
Results
In total, 114 (1.3%) of 8996 patients who requested 
a CXR were diagnosed with lung cancer within 
1 year. Sensitivity was 75.4% and specificity was 
90.2%. The PPV of all symptoms for a diagnosis 
of lung cancer within 1 year of CXR was <1% for 
all individual symptoms except for haemoptysis, 
which had a PPV of 2.9%. PPVs for a diagnosis 
of lung cancer within 2 years of CXR was <1.5% 
for all single symptoms except for haemoptysis, 
which had a PPV of 3.9%.
Conclusion
CXR has limited sensitivity; however, in a 
population with a low prevalence of lung cancer, 
its high specificity and negative predictive value 
means that lung cancer is very unlikely to be 
present following a negative result. Findings also 
support guidance that unexplained haemoptysis 
warrants urgent referral, regardless of CXR result.
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associated with lung cancer are different 
in those who had a positive CXR result 




In this prospective cohort study, the authors 
utilised routinely collected data that had 
been obtained between January 2011 and 
October 2016 from an SR-CXR service at 
Leeds Teaching Hospitals NHS Trust (LTHT), 
England. LTHT is a large trust, with radiology 
and lung cancer services, which serves a 
population of approximately 780 000.10
The SR-CXR service was set up as a 
component of an early-diagnosis campaign 
for lung cancer in Leeds, which was 
initially funded by the National Awareness 
and Early Diagnosis Initiative. The service 
allowed patients aged >50 years who had 
symptoms warranting investigation with 
CXR, as outlined in the NICE guidance, to 
have this investigation without requiring a 
GP referral.11 The relevant symptoms were 
cough, haemoptysis, dyspnoea, chest pain, 
weight loss, and change in voice. Patients 
who had received chest radiography in the 
previous three months were not eligible 
for SR-CXR. The data that were routinely 
collected included symptoms prompting CXR 
and smoking status, as well as the resulting 
CXR report. 
Patients who had a history of lung cancer 
prior to attending for SR-CXR were excluded, 
as were those who were diagnosed with 
an intrathoracic malignancy other than lung 
cancer in the 2 years following SR-CXR. 
The written reports of all SR-CXRs 
were coded as positive or negative, based 
on the criteria used in a Royal College of 
Radiologists national audit.12 These are 
summarised in Supplementary Table S1. To 
confirm satisfactory inter-reviewer reliability 
using this coding system, two authors 
independently coded a sample of 100 CXR 
reports; this yielded a Cohen’s κ score of 0.92, 
indicating a high level of agreement between 
reviewers.
A study database was created using 
symptom and smoking data from the SR-CXR 
service, which was supplemented with the 
codes allocated for each CXR report. For 
patients who underwent >1 SR-CXR during 
the study, each SR-CXR was considered a 
separate event. Demographic data were 
obtained from LTHT’s electronic patient 
records. In order to reflect NICE guidance,3 
patients who had thrombocytosis (defined 
as a platelet count of >400 x 109/L) were 
identified if they had a full blood count (FBC) 
How this fits in 
Chest X-ray (CXR) is the first-line test 
for lung cancer in many countries. 
Some referral guidelines recommend 
CXR for individuals who have particular 
symptoms, based on those symptoms’ 
positive predictive values for lung cancer. 
It is known that CXR does not identify lung 
cancer in around a fifth of cases, but the 
risk of different symptoms being predictive 
of lung cancer in the context of a negative 
CXR is not known. This study, which was 
based on a service that allowed patients 
to request a CXR if they had symptoms of 
lung cancer, suggests the risk of being 
diagnosed with the disease following a 
negative CXR is very low, except in patients 
with haemoptysis. 
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Table 1. Patient characteristics, N = 8996
Characteristic n (%)
Sex
 Male 4441 (49.4)
 Female 4555 (50.6)
Smoking statusa 
 Smoker status not recorded 60 (0.7)
 Smoker/ex-smoker 5951 (66.2)
 Never smoked 2985 (33.2)
Age group, years 
 50–55 1485 (16.5)
 56–60 1484 (16.5)
 61–65 1777 (19.8)
 66–70 1598 (17.8)
 71–75 1205 (13.4)
 76–80 845 (9.4)
 >80 602 (6.7)
Symptoms recorded, n 
 1 3527 (39.2)
 2 3240 (36.0)
 3 1674 (18.6)
 ≥4 555 (6.2)
Thrombocytosis 
 Thrombocytosis in 24 months prior to SR-CXRb  395 (7.2)
Index of Multiple Deprivation score, decile 
 1 (greatest deprivation)  2844 (31.6)
 2 2233 (24.8)
 3  1350 (15.0)
 4 1652 (18.4)
 5 753 (8.4)
 6 29 (0.3)
 7 38 (0.4)
 8 37 (0.4)
 9 35 (0.4)
 10 (least deprivation)  25 (0.3)
aCategory in which stated percentages do not total 100 due to rounding. bOut of 5524 people, who had FBC. 
FBC = full blood count (the blood test routinely used to detect thrombocytosis). SR-CXR = self-requested chest 
X-ray. 
in the 1 year or 2 years prior to SR-CXR from 
the LTHT’s pathology system. 
By cross-referencing with a database of 
all patients who received a multidisciplinary 
team-approved diagnosis of lung cancer in 
LTHT between 2011 and 2018, patients who 
were diagnosed with lung cancer between 
1 year and 2 years following SR-CXR were 
identified. The presence or absence of a 
diagnosis of lung cancer on the database 
within 1 year and 2 years following SR-CXR 
was used to determine whether a diagnosis 
of lung cancer had occurred. 
Statistical analysis
The incidences of patients diagnosed with 
lung cancer within 1 year and 2 years 
following a negative CXR were calculated, 
followed by the incidences of lung cancer 
within 1 year and 2 years by each symptom 
and symptom combination; these are 
equivalent to the observed PPVs of each 
symptom or symptom combination. 
Patients who reported multiple symptoms 
were included in calculations for individual 
symptoms and also for symptom 
combinations. 
Estimates of PPVs adjusted for age, sex, 
and smoking status were obtained from the 
marginal distributions of separate logistic 
regression models predicting lung cancer 
diagnosis within 1 year of a negative CXR for 
each symptom and symptom combination. 
Adjusted PPVs were derived for diagnosis 
within 2 years using the same method. 
Comparing the average risk for people with 
a symptom with the average risk for people 
without that symptom allowed a percentage 
estimate of the additional risk of cancer 
for those with each symptom or symptom 
combination to be derived. All patients in the 
study population had symptoms, so non-
smoking, female patients aged 50–55 years 
were used as a reference category as they 
had the lowest risk of lung cancer. 
A further logistic regression model 
predicting lung cancer diagnosis within 
2 years was constructed for each symptom 
and symptom combination; this included 
the interaction between the indicator for 
that symptom/symptom combination and 
CXR result, as well as the main effects for 
both variables. These interactions explored 
whether the association of each symptom 
and symptom combination with lung cancer 
diagnosis differed between patients with a 
positive CXR and those with a negative CXR.
Statistical analysis was undertaken using 
IBM SPSS Statistics (version 25). 
RESULTS
In total, 9367 SR-CXRs were performed 
during the 70-month study period. Of all 
records, 342 were excluded due to errors 
in the completion of patient information at 
the time of attending for SR-CXR, which 
meant that patient and CXR records could 
not be identified. An additional 16 patients 
were excluded because they had had lung 
cancer diagnosed prior to attending for 
SR-CXR, and a further 13 were excluded 
because they were subsequently diagnosed 
with intrathoracic malignancies other than 
lung cancer. The majority of these excluded 
cases were mesothelioma; however, due to 
data-suppression requirements to maintain 
the anonymity of patients, it was not possible 
to enumerate individual malignancies. 
Following the stated exclusions, the study 
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Table 2. Characteristics of patients diagnosed with lung cancer 
within 1 year and 2 years of SR-CXR
 Diagnosis in 1 year Diagnosis in 2 years 
Characteristic following SR-CXR following SR-CXR
Patients, n (%) 114 (1.3) 154 (1.7)
Mean age, years 69 70 
Male, n (%)  45 (39.5) 64 (41.6)
Smoker/ex-smoker, n (%)   107 (93.9) 145 (94.2)
SR-CXR result, n (%)  
 Positive 86 (75.4) 97 (63.0)
 Negative 28 (24.6) 57 (37.0)
Stage at diagnosis, n (%)  
 Stage I–II 34 (29.8) 50 (32.5)
 Stage III–IV 80 (70.2) 104 (67.5)
Tumour histology, n (%)  
 Adenocarcinoma 38 (33.3) 50 (32.5)
 Squamous cell carcinoma 31 (27.2) 41 (26.6)
 Small cell carcinoma 15 (13.2) 22 (14.3)
 Non-small cell carcinoma not otherwise  17 (14.9) 18 (11.7) 
  stated and large cella
 Unknown 13 (11.4) 23 (14.9)
aNon-small cell group carcinoma not otherwise stated and large cell group data have been combined due to data 
suppression requirements that prevent reporting of identifiable groups of <5. SR-CXR = self-requested chest X-ray.
Table 3. Test characteristics of SR-CXR in the study population
 Lung cancer No diagnosis of  
 diagnosis (within lung cancer (within  
Test characteristic 1 year of SR-CXR) 1 year of SR-CXR) Total, n
Positive x-ray result, n 86 867 953
Negative x-ray result, n 28 8015 8043
Total, n 114 8882 8996
Sensitivity, % (95% CI) 75.4 (67.5 to 83.3) — —
Specificity, % (95% CI) 90.2 (89.6 to 90.9) — —
PPV, % (95% CI)  9.02 (7.21 to 10.8) — —
NPV, % (95% CI) 99.7 (99.5 to 99.8) — —
NPV = negative predictive value. PPV = positive predictive value. SR-CXR = self-requested chest X-ray. 
population was 8996; characteristics of the 
study population are outlined in Table 1. 
A total of 114 patients (1.3%) were 
diagnosed with lung cancer within 1 year 
of having the SR-CXR, of whom 86 (75.4%) 
had a positive SR-CXR result; the remaining 
28 (24.6%) had a negative SR-CXR result 
(Table 2). Negative predictive value for a 
diagnosis of lung cancer within 1 year was 
99.7%. At 2 years following SR-CXR, a total 
of 154 patients (1.7%) were diagnosed with 
lung cancer, of whom 97 (63.0%) had a 
positive SR-CXR result; the remaining 57 
(37.0%) had a negative SR-CXR result. 
Demographic and health characteristics of 
those diagnosed with lung cancer are given 
in Table 2; Table 3 summarises the test 
characteristics of SR-CXRs undertaken in 
the study population.
Observed cancer incidence for patients 
with a negative SR-CXR for 1 year and 
2 years following SR-CXR was 0.35% (95% 
CI = 0.22 to 0.48) and 0.71% (95% CI = 0.53 
to 0.89), respectively (Tables 1 and 2). One-
year and 2-year incidences adjusted for age, 
sex, and smoking status obtained from the 
logistic regression model were 0.27% (95% 
CI = 0.13 to 0.55) and 0.56% (95% CI = 0.37 
to 0.84), respectively (data not shown). 
Figure 1 contains the observed PPVs of lung 
cancer in the 1-year period after SR-CXR 
for single symptoms in the whole study 
population and those participants with a 
negative SR-CXR result. Figure 2 contains 
the observed PPVs of single symptoms and 
symptom combinations in those who had a 
diagnosis of lung cancer within 1 year of a 
negative SR-CXR result. 
Figure 3 contains the adjusted marginal 
mean for single symptoms and symptom 
combinations within 1 year following a 
negative SR-CXR. 
The 1-year and 2-year observed PPVs 
of symptom combinations for the entire 
study population, as well as the 2-year 
adjusted and observed PPVs for those who 
had a negative SR-CXR, are detailed in 
Supplementary Figures S1–S4. 
In total, 4135 and 5524 patients had FBCs 
obtained in the 1 year and 2 years prior to 
SR-CXR, respectively; of these, 217 and 
395 had thrombocytosis. In all analyses 
of thrombocytosis with other symptoms, 
the lower 95% CIs for PPVs were all ≤0 or 
could not be calculated due to insufficient 
cases; as such, inclusion of thrombocytosis 
did not add any discriminative utility in this 
study. The 1-year PPVs for the entire study 
population for thrombocytosis were 1.03 
(95% CI = 0.00 to 2.45) when in combination 
with cough, 2.17 (95% CI = 0.00 to 6.39) 
in combination with chest pain, and 6.67 
(95% CI = 0.00 to 15.59) in combination with 
weight loss (data not shown). There was no 
evidence that symptoms’ associated risk of 
lung cancer differed according to the result 
of the SR-CXR (all interaction P-values 
>0.05).




This study presents the PPVs for developing 
lung cancer with respect to particular 
symptoms when reported in a service that 
allowed patients to have an SR-CXR. The 
findings suggested that, for most symptoms, 
British Journal of General Practice, Online First 2020  4
Figure 1. Individual symptoms’ PPVs (unadjusted) of 
lung cancer diagnosis in 1 year following SR-CXR. As 
thrombocytosis was not used as a qualifying symptom 
for chest x-ray, it has not been included. Error bars 
indicate 95% confidence intervals. PPV = positive 
















Figure 2. Positive predictive values for lung cancer 
diagnosis of symptomsa and symptom combinations 
at 1 year following SR-CXR in those with a negative 
SR-CXR result. aAs thrombocytosis was not used as 
a qualifying symptom for chest X-ray, it has not been 
included. Unbolded data from <5 cases. SR-CXR = self-
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the risk of being diagnosed with lung 
cancer following a negative CXR remains 
very low; the exception was haemoptysis, 
which had a PPV of 2.9%. This provides 
evidence to support current NICE guidance, 
which considers an abnormal CXR result as 
the main criterion for a TWW referral; the 
exception is haemoptysis, which warrants 
referral, even in the absence of a CXR.3 We 
found no evidence that different symptoms 
were associated with a diagnosis of lung 
cancer in those with a negative CXR result 
compared to those who had a positive CXR.
The sensitivity of CXR for a diagnosis of 
lung cancer at 1 year was 75.4%; however, 
coupled with a negative predictive value 
(NPV) of 99%, CXR could be considered well 
suited to its role as a first-line investigation 
in a low-prevalence setting. 
Strengths and limitations 
The large sample size of the study 
population is a strength of this study, along 
with its prospective design. However, the 
study population had a low prevalence of 
lung cancer with only 154 (1.7%) diagnosed 
with the disease within 2 years, of whom 
57 (37.0%) had had a negative SR-CXR 
result. This meant that insufficient cases 
were present to calculate PPVs for several 
symptom combinations. In addition, 
the lack of a control group meant the 
calculation of adjusted PPVs was calculated 
using a within-study comparator based on 
the patients at lowest risk of developing 
lung cancer. 
In determining which study participants 
developed the disease, the authors 
assumed that patients did not move outside 
of the region after having their SR-CXR and 
that diagnoses were recorded in LTHT. It is 
possible that this approach underestimated 
the prevalence of lung cancer if some 
patients moved and were subsequently 
diagnosed elsewhere. 
It is also possible that some cancers 
diagnosed within 1 year and 2 years 
following SR-CXR were not actually 
present at the time of imaging. Although 
the natural history of undetected lung 
cancer is necessarily unknown, estimates 
derived from screening studies suggest 
that, in a large proportion of cases, lung 
cancer develops over some years prior to 
detection.13–15 However, a small proportion 
of cancers develop more rapidly;16 therefore, 
the assumption that a lung cancer that was 
not detected on SR-CXR constitutes a ‘false 
negative’ result requires some qualification, 
particularly at the 2-year interval. 
The study population had a CXR at their 
own request. There could be differences 
between the study population and the 
patient population who are referred for CXR 
by a GP. It is possible that the prevalence of 
lung cancer in the study population is lower 
than in patients who report their symptoms 
to a GP and are then referred for a CXR. 
If this is the case, the pre-test probability 
of lung cancer would be lower and result 
in lower PPVs and sensitivity, and higher 
NPVs and specificity, than in the referred 
population. In addition, although people in 
the study population were deemed eligible 
for CXR because they had symptoms listed 
in current NICE guidance, it is important 
to acknowledge that this guidance was 
based on GP appraisal of patient symptoms 
and did not envisage patient-requested 
investigations. The study population 
was also limited to individuals aged 
>50 years, while NICE guidelines suggests 
investigation for those with symptoms aged 
>40 years.3 
Comparison with existing literature
This study has confirmed the finding of 
previous studies that haemoptysis is the 
symptom most strongly associated with a 
subsequent diagnosis of lung cancer,4–6 and 
also suggests that haemoptysis remains 
an important symptom, even following a 
negative CXR.
Hamilton4 undertook a case–control 
study that linked cancer registry data to GPs’ 
paper and electronic health record symptom 
records; that study did not report CXR 
results. Symptom PPVs for the population of 
the study presented here were much higher 
than those reported by Hamilton, although 
it is not known whether the populations are 
directly comparable; patients’ decisions to 
Figure 3. Adjusted symptom combination marginal 
meansa for lung cancer in the 1-year period following 
negative SR-CXR. aMarginal means are the average 
risks of cancer for different groups (for example, those 
with or without a symptom), taking into account the 
characteristics (such as age and sex) of the people in 
each group. When the average risk for people with a 
symptom is compared with that for people without that 
symptom, it gives an estimate of the additional risk of 
cancer for people with the symptom. Unbolded data 
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self-request a CXR may reflect a greater 
underlying concern that serious disease is 
present, compared with those presenting 
to a GP with symptoms prior to a decision 
having been made about investigation with 
CXR, or those who mention symptoms to a 
GP while attending for other reasons. 
Previous findings that thrombocytosis is 
associated with an increased risk of lung 
cancer17 were not replicated in this study. 
The relatively small numbers of patients 
diagnosed with lung cancer and the number 
of those with thrombocytosis is likely to have 
rendered this study underpowered to detect 
such an association. Another possibility is 
that the population selected for a FBC and 
the population that requested a CXR in this 
study — that is, those selected for testing by 
their GP or those who opted to undergo a 
CXR themselves — were at already-elevated 
risk of serious disease compared with the 
wider population.18 This related mechanism 
of test selection bias may have obscured 
the capacity to differentiate elevated risk 
of thrombocytosis as well as patient self-
selection to undergo CXR. 
Implications for practice
This study provides evidence to support 
existing guidance that advocates urgent 
referral for unexplained haemoptysis. The 
study also suggests that CXR's present 
role as a first-line test for lung cancer in 
symptomatic patients is appropriate. 
Clinicians should understand that 
although a diagnosis of lung cancer is 
uncommon after a negative CXR, the 
high NPV of the modality reflects the low 
prevalence of lung cancer among those who 
have symptoms that are associated with the 
disease, since most of these symptoms are 
common and non-specific. Therefore, it is 
important to remember that CXR does not 
detect over a fifth of cases of lung cancer 
and that diagnosis of lung cancer following 
a negative CXR, though unlikely, remains 
possible. This insight supports the use of 
a safety netting approach even following 
a negative CXR, by advising patients to 
represent if their symptoms persist or 
worsen within a particular timeframe. 
Clinicians can, with confidence, inform 
patients who have not had haemoptysis 
that a diagnosis of lung cancer following a 
negative CXR is very unlikely and that the 
benefits of immediate further investigation 
are, in most cases, unlikely to justify the 
harms, costs, and inconvenience. 
As the precise level of risk that might be 
considered acceptable will vary between 
individuals and clinicians, a shared 
decision-making approach is prudent 
when considering what action to take when 
symptoms continue, despite a negative 
CXR. Clinicians should remember that, 
even in patients who appear to be at low 
risk, a negative CXR does not eliminate 
the possibility of lung cancer and, in some 
cases, further investigation should be 
considered if symptoms persist or evolve. 
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